Error message

Deprecated function: The each() function is deprecated. This message will be suppressed on further calls in theme_biblio_custom() (line 367 of /home/phcogcommn/

GC-MS Analysis of Frankincense Extracts which Inhibit the Growth of Bacterial Triggers of Selected Autoimmune Diseases


Pharmacognosy Communications,2016,6,1,10-22.
Published:December 2015
Type:Original Article

GC-MS Analysis of Frankincense Extracts which Inhibit the Growth of Bacterial Triggers of Selected Autoimmune Diseases

Isaac Biggs1, Joseph Sirdaarta1,2, Alan White1, Ian Edwin Cock1,2

1School of Natural Sciences, Nathan Campus, Griffith University, 170 Kessels Road, Nathan, Queensland 4111, AUSTRALIA.

2Environmental Futures Research Institute, Nathan Campus, Griffith University, 170 Kessels Road, Nathan, Queensland 4111, AUSTRALIA.


Introduction: Frankincense has been used traditionally for the inhibition of microbial growth and for the treatment of rheumatic diseases. Despite this, frankincense extracts are yet to be tested for the ability to inhibit the growth of the bacterial triggers of autoimmune inflammatory diseases. Methods: Solvent extracts prepared from commercially obtained frankincense were analysed for the ability to inhibit the growth of bacterial species associated with initiating rheumatoid arthritis (P. mirabilis), ankylosing spondylitis (K. pneumoniae) and multiple sclerosis (A. baylyi, P. aeruginosa) by disc diffusion assay, and quantified by MIC determination. Toxicity was determined by Artemia franciscana bioassay.The most potent inhibitory extracts were investigated using non-targeted GC-MS head space analysis (with screening against a compound database) for the identification and characterisation of individual components in the crude plant extracts. Results: Methanolic and aqueous frankincense extracts inhibited the growth of all bacterial species. The growth inhibition of these extracts was particularly notable against P. mirabilis and K. pneumoniae, with MIC values generally ≤ 1000 μg/mL for both reference and clinical bacterial strains. Indeed, the MIC values of the methanolic extract against P. mirabilis, and for the aqueous extract against K. pneumonia, were as low as 59.6 and 75.2 μg/mL respectively. The methanolic and aqueous extracts also inhibited the growth of A. baylyi and P. aeruginosa. However, with the exception of the growth inhibition of A. baylyi by the aqueous extract (MIC=4313 μg/mL: moderate inhibitory activity), the MICs against these bacteria was indicative of only low inhibitory activity. The ethyl acetate, chloroform and hexane extracts also inhibited the growth of all bacterial species, albeit with low efficacy (MIC values generally >5000 μg/mL against all bacterial species). All frankincense extracts were non-toxic in the Artemia franciscana bioassay, with LC50 values substantially above 1000 μg/mL. Non-biased GC-MS headspace analysis of the methanolic and aqueous extracts putatively identified a high diversity of monoterpenoids and sesquiteriterpenoids. Conclusion: The lack of toxicity and the inhibitory activity of the methanolic and aqueous frankincense extracts against microbial triggers of rheumatoid arthritis and ankylosing spondylitis indicates their potential in the treatment and prevention of these diseases.

Founded:  In 2004, as the PHCOG.NET – a non-profit private organization dedicated to Natural Products Research leading to develop promising drugs. Our main mission is to make information on herbal drug research readily available in different formats to suit the individual needs.

Pharmacognosy Communications [Phcog Commn.] is a new quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the  publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.

The journal aims to cater the latest outstanding developments in the field of pharmacognosy and natural products and drug design covering but not limited to the following topics:

  • Pharmacognosy and pharmacognistic investigations
  • Research based ethnopharmacological evaluations
  • Biological evaluation of crude extracts, essential oils and pure isolates
  • Natural product discovery and evaluation
  • Mechanistic studies
  • Method and technique development and evaluation
  • Isolation, identification and structural elucidation of natural products
  • Synthesis and transformation studies

Distinctions:  The most widely read, cited, and known Pharmacognosy Communications and website is well browsed with all the articles published. More than 20,000 readers in nearly every country in the world each month

Aim and Scope | Editorial Board | Indexed & Abstracted | Instruction to Authors | Manuscript Submission & Charges

Subjects Covered : Natural Products, Pharmacognosy, Phytochemistry, Marine Pharmacognosy and Zoo Pharmacognosy
ISSN :2249-0159 (Print) ; 2249-0167 (Online) Frequency : Quarterly Rapid at a time publication (4 issues/year)

Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online  publication is 45 days.
Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.